Lifestyle treatments in cystic fibrosis: The NHS should pay.

Robert Ian Ketchell

Journal: Paediatric respiratory reviews 2017;20 Suppl():12-4

PMID: 27373763

Full Text on Elsevier Science View on PubMed

Abstract

With the NHS under increasing financial pressure and healthcare costs soaring year on year, it is perhaps not surprising that assessment agencies focus on cost-effectiveness analysis when assessing new therapies. Such an approach does not however, always take sufficient account of treatment burden, lifestyle and patient choice and therefore new equally effective but perhaps "easier to take" formulations and faster delivery systems for current therapies do not always take precedence in current treatment guidelines. In arguing that the NHS should pay for so-called lifestyle treatments in cystic fibrosis the counterintuitive nature of some of the current decision making is discussed and a more holistic approach to improve NHS efficiency is presented.

Address: All Wales Adult Cystic Fibrosis Centre. University Hospital Llandough, Penlan Road, Penarth. CF64 2XX. Electronic address: [email protected].

DOI: 10.1016/j.prrv.2016.06.006

Link outs

Free resources

Medical:

Other Literature Sources:

https://scite.ai/reports/27373763

Subscription / membership required

Full Text Sources:

MeSH Terms: Cystic Fibrosis, England, Humans, Life Style, Quality of Life, State Medicine